{
    "root": "06c3071e-36b7-4d88-aaa8-2010a3358042",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "sucralfate"
    },
    "value": "20250313",
    "ingredients": [
        {
            "name": "SUCRALFATE",
            "code": "XX73205DH5"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SORBITOL SOLUTION",
            "code": "8KW3E207O2"
        },
        {
            "name": "MALTODEXTRIN",
            "code": "7CVR7L4A2D"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "LACTIC ACID",
            "code": "33X04XA5AT"
        },
        {
            "name": "METHYLCELLULOSE (4000 CPS)",
            "code": "MRJ667KA5E"
        },
        {
            "name": "DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER (40/60 W/W; 1000000 PA.S)",
            "code": "83D19O7250"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.",
    "contraindications": "Active Duodenal Ulcer: The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach.\n                  Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension.\n                  While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. \n                  \n                     Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See PRECAUTIONS, Geriatric Use).\n                  Call your doctor for medical advice about side effects. You may report side effects to Allergan USA, Inc. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",
    "warningsAndPrecautions": "Sucralfate Oral Suspension 1 g/10 mL is a light pink to pink suspension supplied in the following: \n                  \n                     NDC 64380-149-01: 420 mL bottles\n                     NDC 64380-149-03: 5 x 10 mL unit-dose cups in a tray.\n                     NDC 64380-149-04: 10 x 10 mL unit-dose cups in a tray, 3 trays per carton.\n                     NDC 64380-149-05: 10 x 10 mL unit-dose cups in a tray, 4 trays per carton.\n                     NDC 64380-149-06: 10 x 10 mL unit-dose cups in a tray, 5 trays per carton.\n                     NDC 64380-149-07: 10 x 10 mL unit-dose cups in a tray, 10 trays per carton.\n                  \n                  \n                     SHAKE WELL BEFORE USING AVOID FREEZING.\n                  Store at controlled room temperature 20-25°C (68-77°F) [see USP].\n                  Rx Only\n                  \n                     Manufactured by: \n                  \n                  Strides Pharma Science Limited.\n                  Bengaluru – 562106, India\n                  \n                     Distributed by: \n                  \n                  Strides Pharma Inc. \n                  East Brunswick, NJ 08816 \n                  \n                     Revised: 03/2024",
    "adverseReactions": "Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients."
}